Hemenway, G., Ross, E. A., Schwebel, C., Chen, L., Dotan, E., Anari, F., Ghatalia, P., Kydd, A. R., Zibelman, M. R., Plimack, E. R., Geynisman, D. M. (2026). A phase 2 study of gemcitabine plus carboplatin as second-line therapy after prior enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps901